Kansanterveyslaitos KTL

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lindholm LH; Ibsen H; Dahlöf B; Devereux RB; Beevers G; de Faire U; Fyhrquist F; Julius S; Kjeldsen SE; Kristiansson K; Lederballe-Pedersen O; Nieminen MS; Omvik P; Oparil S; Wedel H; Aurup P; Edelman J; Snapinn S; LIFE Study Group; Tuomilehto J; Sarti C
Lancet (2002)

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; for the LIFE Study Group; Tuomilehto J; Sarti C; Ylihärsilä H
Lancet : 9311 (2002)

Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study

Dahlöf B; Devereux RB; Julius S; Kjeldsen SE; Beevers G; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; LIFE Study Group; Tuomilehto J; Sarti C
Hypertension (1998)

Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarthan Intervention For Endpoint Reduction (LIFE) Substudy

Kjeldsen SE; Dahlöf B; Devereux RB; Julius S; Aurup P; Edelman J; Beevers G; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Snapinn S; Wedel H; for the LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
JAMA (2003)

Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study

Wachtell K; Bella JN; Liebson PR; Gerdts E; Dahlöf B; Aalto T; Roman MJ; Papademetriou V; Ibsen H; Rokkedal J; Devereux RB; Sarti C; Tuomilehto J
Hypertension (2000)

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Hoieggen A; Alderman MH; Kjeldsen SE; Julius S; Devereux RB; De Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederball-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Chen C; Dahlöf B; LIFE Study Group; Sarti C; Tuomilehto J; Ylihärsilä H
Kidney Int (2004)

The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, Design and Methods

Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; The LIFE Study Group; Tuomilehto J; Sarti C
AM J HYPERTENS : 7 (1997)

"Ibsen H" - Selaus tekijän mukaan Kansanterveyslaitos KTL

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol ﻿

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol ﻿

Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study ﻿

Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarthan Intervention For Endpoint Reduction (LIFE) Substudy ﻿

Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study ﻿

The impact of serum uric acid on cardiovascular outcomes in the LIFE study ﻿

The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study. Rationale, Design and Methods ﻿